There were 1,577 press releases posted in the last 24 hours and 439,143 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical…

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image